Navigation Links
Statement From Eli Lilly and Company Regarding Stolen Company Products From Enfield, Connecticut Distribution Operations
Date:3/17/2010

INDIANAPOLIS, March 17 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today issued a statement and details regarding the stolen company products from its distribution operations in Enfield, Connecticut on Sunday, March 14.  

Lilly is working with the U.S. Food and Drug Administration's Office of Criminal Investigations (FDA), and other law enforcement officials, to recover cases of select lots of pharmaceutical products that were stolen from one of Lilly's United States distribution centers located in Enfield, Connecticut, on Sunday, March 14, 2010.  A list of products stolen from the facility can be found at the bottom of this press release.

"Since early Sunday morning, Lilly has taken quick and appropriate actions to ensure the safety of our medicines," said Dr. Fionnuala M. Walsh, Lilly's senior vice president of global quality.  "The U.S. pharmaceutical distribution system is tightly controlled and monitored, making it extremely difficult for stolen product to make it to patients through legitimate channels. However, we will continue to work closely with local and federal law enforcement authorities, the FDA, and our distribution partners to maintain the integrity of our drug supply chain."

Product from the affected lots which had been delivered from Lilly to retailers, wholesalers or institutions prior to March 14 was approved for its intended use and is not affected by this event.  Product containing these lot numbers has been distributed by Lilly within the United States, Puerto Rico and its territories.

These medicines require a prescription for purchase.  Consumers should purchase Lilly products only from well-established and reputable retailers.  Lilly recommends that consumers always inspect the product and label for signs of tampering before opening.  

Lilly is advising practitioners, retailers and consumers to check all pharmaceutical products for signs of tampering or damage prior to purchase and/or use.  Pharmacists and other health care professionals should not use the product if it has been removed from the sealed bottle or container, if the induction seal has been compromised, or in the case of glass vials, if the flip cap appears to have been disturbed in any way.  

To assist the FDA and the law enforcement agencies in their investigation, Lilly stopped distributing product with the affected lot numbers on Monday, March 15, 2010.

Lilly is asking for the public's help in reporting any information regarding the stolen products to FDA's Office of Criminal Investigations (OCI) by calling (800) 551-3989 or by visiting the OCI website www.fda.gov/OCI.

For medical or other related inquiries about this matter, contact Lilly at 1-800-LILLYRX (1-800-545-5979).

Impacted Products

    
    
                              National Drug Code
    Product Description       (NDC)               Lot Number   Expiry Date
    -------------------       ------------------  ----------   -----------
    ALIMTA FINJ 500MG X1
     lyophilizedVIAL AM       00002-7623-01       A671076C      8/31/2011
    --------------------      -------------       --------      ---------
    CYMBALTA CAP 30MG X 30
     BTL AM                   00002-3240-30       A643056A      5/31/2012
    ----------------------    -------------       --------      ---------
    CYMBALTA CAP 30MG X 30
     BTL AM                   00002-3240-30       A662278C      7/31/2012
    ----------------------    -------------       --------      ---------
    CYMBALTA CAP 30MG X 30
     BTL AM                   00002-3240-30       A662281A      7/31/2012
    ----------------------    -------------       --------      ---------
    CYMBALTA CAP 60MG X30BOTL
     AM                       00002-3270-30       A672999A      9/30/2011
    ------------------------- -------------       --------      ---------
    CYMBALTA CAP 60MG
     X1000BOTL AM             00002-3270-04       A685790A     10/31/2011
    -----------------         -------------       --------     ----------
    EFFIENT TAB 10MG X30BOTL
     AM                       00002-4759-30       A650259A     12/31/2010
    ------------------------  -------------       --------     ----------
    GEMZAR 200MG VIALS        00002-7501-01       A670185A      8/31/2011
    ------------------        -------------       --------      ---------
    GEMZAR 1 GRAM VIALS       00002-7502-01       A668160D      8/31/2011
    -------------------       -------------       --------      ---------
    GEMZAR 1 GRAM VIALS       00002-7502-01       A670177A      9/30/2011
    -------------------       -------------       --------      ---------
    GEMZAR 1 GRAM VIALS       00002-7502-01       A670180A      8/31/2011
    -------------------       -------------       --------      ---------
    GEMZAR 1 GRAM VIALS       00002-7502-01       A670182A      9/30/2011
    -------------------       -------------       --------      ---------
    PROZAC PULV 20MG X 30
     BOTL DP                  00777-3105-30       A599046D      1/31/2012
    ---------------------     -------------       --------      ---------
    PROZAC PULV 20MG X 30
     BOTL DP                  00777-3105-30       A689619D     10/31/2012
    ---------------------     -------------       --------     ----------
    PROZAC PULV 40MG X 30
     BOTL DP                  00777-3107-30       A602567A      1/31/2012
    ---------------------     -------------       --------      ---------
    STRATTERA CAP 10MG X 30
     BOTL AM                  00002-3227-30       A621189A      3/31/2012
    -----------------------   -------------       --------      ---------
    STRATTERA CAP 25MG X 30
     BOTL AM                  00002-3228-30       A678353A      2/29/2012
    -----------------------   -------------       --------      ---------
    STRATTERA CAP 60MG X 30
     BOTL AM                  00002-3239-30       A621202A      3/31/2012
    -----------------------   -------------       --------      ---------
    STRATTERA CAP 100MG
     X30BOTL AM               00002-3251-30       A621205C      3/31/2012
    -------------------       -------------       --------      ---------
    SYMBYAX CAP 6/25MG X 30
     BOTL AM                  00002-3231-30       A562684A     10/31/2011
    -----------------------   -------------       --------     ----------
    ZYPREXA TAB 2.5MG X30BOTL
     AM                       00002-4112-30       A644710A      5/31/2011
    ------------------------- -------------       --------      ---------
    ZYPREXA TAB 5MG X30BOTL
     AM                       00002-4115-30       A668322A      8/31/2011
    -----------------------   -------------       --------      ---------
    ZYPREXA TAB 7.5MG X30BOTL
     AM                       00002-4116-30       A646193A      5/31/2011
    ------------------------- -------------       --------      ---------
    ZYPREXA TAB 10MG X30BOTL
     AM                       00002-4117-30       A641350C      5/31/2012
    ------------------------  -------------       --------      ---------
    ZYPREXA TAB 10MG X30BOTL
     AM                       00002-4117-30       A668323A      8/31/2012
    ------------------------  -------------       --------      ---------
    ZYPREXA TAB 15MG X 1000
     BOTL AM                  00002-4415-04       A647860A      5/31/2012
    -----------------------   -------------       --------      ---------
    ZYPREXA TAB 15MG X30BOTL
     AM                       00002-4415-30       A690238A     10/31/2012
    ------------------------  -------------       --------     ----------
    ZYPREXA TAB 20MG X30BOTL
     AM                       00002-4420-30       A677956A      8/31/2012
    ------------------------  -------------       --------      ---------
    ZYPREXA TAB 20MG X30BOTL
     AM                       00002-4420-30       A677958C      8/31/2012
    ------------------------  -------------       --------      ---------
    ZYPREXA TAB ID100 10MG
     XID100BLCD AM            00002-4117-33       A632252D      4/30/2012
    ----------------------    -------------       --------      ---------
    ZYPREXA ZYDIS TAB 5MG X
     30 SACH AM               00002-4453-85       976041A        7/1/2012
    -----------------------   -------------       -------        --------
    ZYPREXA ZYDIS TAB 10MG X
     30 SACH AM               00002-4454-85       971159A        7/1/2012
    ------------------------  -------------       -------        --------
    ZYPREXA ZYDIS TAB 20MG X
     30 SACH AM               00002-4456-85       963999A        5/1/2012
    ------------------------  -------------       -------        --------
    
    

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information -- for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com. C-LLY

Alimta® (pemetrexed disodium)

Cymbalta® (duloxetine hydrochloride)

Effient™ (prasugrel)

Gemzar® (gemcitabine hydrochloride)

Prozac® (fluoxetine hydrochloride)

Strattera® (atomoxetine hydrochloride)

Symbyax (olanzapine / fluoxetine hydrochloride)

Zyprexa® (olanzapine)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )

SOURCE Eli Lilly and Company

Back to top
'/>"/>
SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Abbott Statement: ACCORD Lipid Results Support Treatment Guidelines for Fibrate Use
2. Pew Statement on Congressional Hearing Regarding FDA Drug Safety Reforms
3. SCAI Statement on the CREST Study Findings: Carotid Stenting is as Safe and Effective as Carotid Surgery in Patients at Risk for Stroke
4. GSK Statement on FDAs Proposed Label Revisions for Some Asthma Medicines
5. SCAI Statement on the Hospitalization of Former President Bill Clinton
6. Oramed Pharmaceuticals Announces Filing of Two Registration Statements
7. Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering
8. Viral Genetics Files 2009 3rd Quarter Consolidated Financials and Information Statement at Pinksheets.com
9. Statement From the Consumer Healthcare Products Association(CHPA) on Annual Monitoring the Future Survey on Drug Abuse
10. Sinovac Files Shelf Registration Statement
11. Derma Sciences Files S-1 Registration Statement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/19/2017)... RALEIGH, N.C. , July 19, 2017  Mako ... Veteran Affairs, and the Military Family Assistance Fund (MFA) ... Louisiana to visit with their families one ... the funding to coordinate the travel and logistics needed ... supporting our deployed soldiers and their families. We just ...
(Date:7/14/2017)... 13, 2017 It should come as no surprise ... is in the midst of a crippling opioid epidemic. According ... the number of overdose deaths from opiate-based medications has quadrupled, ... a million dead from 2001 to 2015". During this time, ... has similarly quadrupled, drawing a compelling link between prescription and ...
(Date:7/12/2017)... CarpalAID is a revolutionary new product that relieves painful carpal tunnel ... syndrome affects more than 8 million people a year. Women suffer ... common methods of treating CTS are painful surgery, the use of ... ... is a clear patch worn on the palm of the hand. ...
Breaking Medicine Technology:
(Date:7/21/2017)... (PRWEB) , ... July 21, 2017 , ... ... Philadelphia and Theater of Witness , was awarded a $300,000 grant ... humanities program which fosters empathy, comfort with ambiguity and the recognition of one’s ...
(Date:7/21/2017)... ... July 21, 2017 , ... The Margarian Law Firm has filed a ... ginger ale for allegedly containing no ginger. Dr. Pepper produces the “Canada Dry” brand ... Gegham Margaryan alleges Canada Dry Ginger Ale claims on its bottle that it is ...
(Date:7/21/2017)... ... July 21, 2017 , ... MedMatchPlus+ has launched ... of acceptance to a residency in a United States hospital. Being accepted into ... U.S. , According to data released by the ECFMG®, every year, 50 percent ...
(Date:7/21/2017)... (PRWEB) , ... July 21, 2017 , ... West Dermatology ... Tuantu Doan Vu, PA-C. Beginning July 17, 2017, Ms. Vu will join West Dermatology’s ... years of experience in dermatology, skin cancer , and more. She graduated from ...
(Date:7/21/2017)... ... 21, 2017 , ... How physicians and athletic trainers assess ... researchers presenting their work at the American Orthopaedic Society for Sports Medicine’s ... the patterns of change in concussion symptom presentation, diagnostic tools used and length ...
Breaking Medicine News(10 mins):